Edgewise Therapeutics (EWTX) Competitors $16.10 +0.76 (+4.92%) As of 11:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EWTX vs. RYTM, CRSP, AXSM, NUVL, TGTX, LEGN, MTSR, PCVX, KRYS, and ARWRShould you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), Axsome Therapeutics (AXSM), Nuvalent (NUVL), TG Therapeutics (TGTX), Legend Biotech (LEGN), Metsera (MTSR), Vaxcyte (PCVX), Krystal Biotech (KRYS), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Edgewise Therapeutics vs. Its Competitors Rhythm Pharmaceuticals CRISPR Therapeutics Axsome Therapeutics Nuvalent TG Therapeutics Legend Biotech Metsera Vaxcyte Krystal Biotech Arrowhead Pharmaceuticals Edgewise Therapeutics (NASDAQ:EWTX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings. Does the media favor EWTX or RYTM? In the previous week, Edgewise Therapeutics had 1 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 3 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.75 beat Edgewise Therapeutics' score of 0.63 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has higher earnings & valuation, EWTX or RYTM? Edgewise Therapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdgewise TherapeuticsN/AN/A-$133.81M-$1.55-10.39Rhythm Pharmaceuticals$130.13M51.02-$260.60M-$3.01-33.21 Which has more risk and volatility, EWTX or RYTM? Edgewise Therapeutics has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Is EWTX or RYTM more profitable? Edgewise Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -117.13%. Edgewise Therapeutics' return on equity of -30.65% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Edgewise TherapeuticsN/A -30.65% -29.18% Rhythm Pharmaceuticals -117.13%-1,831.43%-48.33% Do analysts rate EWTX or RYTM? Edgewise Therapeutics presently has a consensus target price of $38.83, suggesting a potential upside of 141.13%. Rhythm Pharmaceuticals has a consensus target price of $106.64, suggesting a potential upside of 6.70%. Given Edgewise Therapeutics' higher probable upside, equities analysts plainly believe Edgewise Therapeutics is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.69Rhythm Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.94 SummaryEdgewise Therapeutics beats Rhythm Pharmaceuticals on 8 of the 13 factors compared between the two stocks. Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EWTX vs. The Competition Export to ExcelMetricEdgewise TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.70B$12.30B$9.08B$10.58BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-10.4121.9786.1627.45Price / SalesN/A273.38539.92202.26Price / CashN/A47.1237.9261.55Price / Book3.3310.2813.056.77Net Income-$133.81M-$52.40M$3.30B$275.88M7 Day Performance7.37%6.10%4.55%2.63%1 Month Performance9.19%15.74%9.73%9.10%1 Year Performance-46.90%32.50%85.10%35.69% Edgewise Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EWTXEdgewise Therapeutics2.5974 of 5 stars$16.11+4.9%$38.83+141.1%-46.1%$1.70BN/A-10.4160Analyst ForecastRYTMRhythm Pharmaceuticals3.5235 of 5 stars$96.80-2.2%$106.64+10.2%+108.4%$6.45B$156.29M-32.26140Analyst ForecastCRSPCRISPR Therapeutics1.4625 of 5 stars$70.50+0.4%$71.50+1.4%+69.9%$6.42B$35M-12.99460Analyst ForecastAXSMAxsome Therapeutics4.7811 of 5 stars$118.39-1.6%$177.93+50.3%+40.0%$6.05B$495.03M-23.91380Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionNUVLNuvalent2.9489 of 5 stars$83.08-1.4%$118.89+43.1%-17.1%$5.99BN/A-16.9440Analyst ForecastTGTXTG Therapeutics4.4452 of 5 stars$36.81+0.1%$49.00+33.1%+63.7%$5.84B$454.07M99.46290Positive NewsAnalyst ForecastAnalyst RevisionLEGNLegend Biotech2.5978 of 5 stars$31.39-0.2%$71.33+127.3%-33.0%$5.79B$627.24M-35.652,609News CoverageAnalyst ForecastMTSRMetseraN/A$52.35-0.3%$55.75+6.5%N/A$5.50BN/A0.0081Analyst ForecastPCVXVaxcyte2.4127 of 5 stars$40.73-1.2%$106.25+160.9%-63.5%$5.30BN/A-9.92160News CoverageKRYSKrystal Biotech4.5219 of 5 stars$179.51-2.1%$209.00+16.4%+7.1%$5.26B$359.21M36.91210Analyst ForecastARWRArrowhead Pharmaceuticals4.0816 of 5 stars$37.55+0.1%$43.14+14.9%+105.0%$5.22B$3.55M-29.49400Analyst Forecast Related Companies and Tools Related Companies Rhythm Pharmaceuticals Competitors CRISPR Therapeutics Competitors Axsome Therapeutics Competitors Nuvalent Competitors TG Therapeutics Competitors Legend Biotech Competitors Metsera Competitors Vaxcyte Competitors Krystal Biotech Competitors Arrowhead Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EWTX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
